CV Risk Lower With Metformin in T2DM & #43; Reduced Kidney Function
THURSDAY, Sept. 19, 2019 -- Treatment with metformin versus sulfonylureas is associated with a reduced risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes and reduced kidney function, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Metformin | Pharmaceuticals | Study | Urology & Nephrology